Azerbaijan State Registration Suspension: Four Grounds and a Full-Chain Stop

1. Key takeaways

Part 11 of Rules No. 345 provides that, except in the cases set by Article 25 of the Law on Licenses and Permits, where a registered medicine, pharmaceutical substance or device falls into one of the following situations, the Ministry of Health suspends the State registration (Articles 11.1.1 to 11.1.4):

11.1.1 adverse effects not stated in the instructions for use occur even when the device is used as intended and correctly in accordance with those instructions;

11.1.2 a benefit/risk assessment conducted under Resolution No. 503 of the Cabinet of Ministers of 25 December 2019 on Pharmacovigilance Rules concludes that the medicine or pharmaceutical substance lacks or has insufficient therapeutic effectiveness;

11.1.3 packaging and labelling requirements are not observed, and a formal warning issued by the agency to the certificate holder has not been acted upon;

11.1.4 a proven fact that a registered medicine is of poor quality, ineffective or unsafe is established under Article 4.3-1 of the Law on Medicines, and a decision to prohibit its use within Azerbaijan is taken on that basis.

The consequences (Article 11.2): import, domestic production for sale, sale and use are all stopped; in addition, a decision is taken under Resolution No. 460 of 27 November 2019 on the Rules for the Withdrawal of Medicines on whether to recall products in circulation. Article 11.3 requires immediate written information to the certificate holder; Article 11.4 provides that the suspension lasts until the situation is eliminated and is published in the media under Article 16 of the Law on Medicines.

2. Legal basis

• Resolution No. 345 of the Cabinet of Ministers of the Republic of Azerbaijan of 18 July 2024 approving the Rules for the State Registration of Medicines, Pharmaceutical Substances and Medical Devices, Their Entry in the State Register and the Maintenance of the State Register (in force from 19 July 2024; Xalq qəzeti No. 151 of 20 July 2024; Legislative Collection 2024, No. 7, Article 906; repealing Resolution No. 108 of 13 July 2007 with effect from 20 July 2024): Articles 11.1.1 to 11.1.4 (the 4 suspension grounds), Article 11.2 (all stops on import, production, sale and use; recall decision under Resolution No. 460), Article 11.3 (immediate written notification of the certificate holder), Article 11.4 (suspension until the situation is eliminated; media publication under Article 16 of the Law on Medicines), Article 10.6 (Register entry of the suspension and its date).
• Resolution No. 503 of the Cabinet of Ministers of the Republic of Azerbaijan of 25 December 2019 on Pharmacovigilance Rules (the basis of the benefit/risk assessment), and Resolution No. 460 of the Cabinet of Ministers of the Republic of Azerbaijan of 27 November 2019 on the Rules for the Withdrawal of Medicines (the basis of recalls).
• Law of the Republic of Azerbaijan on Licenses and Permits (No. 176-VQ of 15 March 2016), Articles 18.2.1–18.2.3, 19.9, 25 and 26.1: Article 25 (other statutory grounds for suspension), Article 26.1 (other statutory grounds for revocation).
• Law of the Republic of Azerbaijan on Medicines (No. 208-IIIQ, adopted 22 December 2006, in force 28 February 2007, Legislative Collection 2007, No. 2, Article 70), as amended by Law No. 979-VIQD of 14 July 2023 (adding Articles 1-1 and 9-1 as new provisions, Legislative Collection 2023, No. 8, Article 1127): Article 4.3-1 (the provision cited by Article 11.1.4), Article 16 (media publication).

3. Expert insights

Insight one: of the four grounds, Article 11.1.3 is the one devices realistically trigger. Article 11.1.2 (therapeutic effectiveness) and Article 11.1.4 (poor quality) are drafted around medicines; Article 11.1.1 on unstated adverse effects has some application to devices, but Article 11.1.3 (non-compliant packaging and labelling with an unheeded warning) is the only ground that is entirely neutral and applies to devices and medicines on equal terms. Its probability of being triggered is far higher than that of the other three.

Insight two: Article 11.1.3 has a warning-first protection mechanism. The provision requires that a formal warning issued by the agency to the certificate holder has not been acted upon before suspension can occur. In other words, the regulator must warn first and give one chance to remediate. This means the certificate holder must have a mechanism that actually receives and reads official warnings — the document-forwarding obligation in the authorisation letter directly determines the outcome here.

Insight three: the consequences under Article 11.2 stop the whole chain, not only import. Import, domestic production for sale, sale and use — all four stop. For a distributor holding stock, this is a heavier blow than a fine. During suspension, a decision on whether to recall products in circulation must also be taken under Resolution No. 460 — the recall scope may extend to products already sold.

Insight four: Article 11.4 makes suspension a public event. Suspension information is published in the media under Article 16 of the Law on Medicines, and Article 10.6 requires the Register to record the fact and the date of suspension. Suspension is a publicly searchable status, and tender eligibility and channel trust both suffer. Because the suspension lasts until the situation is eliminated, the speed of remediation directly determines the length of the commercial loss.

Insight five: Article 11.1.4 cites Article 4.3-1 of the Law on Medicines, which is not in the device exclusion list of Article 1-1. This means Article 4.3-1 applies to devices as well — where a registered product is proven to be of poor quality, ineffective or unsafe, a decision to prohibit its use within the country can be taken on that basis. Practical estimate: on how ineffectiveness is determined for a device, it is advisable to obtain written confirmation of the criteria from the AEC.

4. Practical recommendations

1. Build a 48-hour response mechanism for formal AEC warnings: start remediation on receipt and reply in writing with the remediation result within the warning period.
2. State in the authorisation letter and internal procedures that the local entity forwards regulatory correspondence to the foreign manufacturer within 1 working day of receipt.
3. Make packaging and labelling compliance a mandatory quarterly inspection item (Article 11.1.3).
4. Maintain a suspension contingency plan: stock freeze, channel notification and recall assessment under Resolution No. 460 are started in parallel.
5. Monitor Register and media suspension entries and brief channel partners in writing on remediation progress within 48 hours of any such entry.
6. Obtain written confirmation from the AEC on how the ineffectiveness criteria of Article 4.3-1 apply to devices.

5. Verification checklist

• □ A 48-hour response mechanism for formal AEC warnings is in place.
• □ The authorisation letter states the document-forwarding obligation and its deadline.
• □ Packaging and labelling compliance is a mandatory quarterly inspection item.
• □ A suspension contingency plan (stock freeze, channel notification, recall assessment) has been drawn up.
• □ A 48-hour channel briefing mechanism for suspension entries is in place.
• □ Written AEC confirmation on the Article 4.3-1 criteria for devices has been obtained.

• Article 43 — Cancellation of State registration: 5 grounds and 2-working-day service: https://www.grzanglobal.com/azerbaijan-medical-device-registration/cancellation-of-state-registration/
• Article 44 — Device vigilance under the current rules: the spillover of the Pharmacovigilance Rules: https://www.grzanglobal.com/azerbaijan-medical-device-registration/vigilance-current-legal-basis/
• Article 24 — Labelling and packaging: Azerbaijani-language colour mock-ups: https://www.grzanglobal.com/azerbaijan-medical-device-registration/labelling-and-packaging-azerbaijani-mockups/

Regulatory information verified as of October 30, 2026.

GRZAN supports manufacturers and authorised representatives preparing registration dossiers and post-market compliance documentation for the Azerbaijan market, from warning-response procedures and labelling audits to suspension contingency planning and recall assessments under Resolution No. 460. For tailored assistance with your Azerbaijan medical device documentation, contact us at info@grzanglobal.com.